Supernus Pharmaceuticals, Inc.
(NASDAQ : SUPN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. -1.52%26.0114.1%$153.05m
AMRNAmarin Corp. Plc -1.99%17.511.7%$94.15m
CTLTCatalent, Inc. -0.26%58.652.2%$74.64m
RVMDRevolution Medicines, Inc. -0.94%30.710.0%$72.19m
GWPHGW Pharmaceuticals Plc -2.86%124.896.2%$59.37m
JAZZJazz Pharmaceuticals Plc -0.76%134.472.3%$58.43m
AXSMAxsome Therapeutics, Inc. -2.34%90.421.9%$55.15m
UTHRUnited Therapeutics Corp. -0.20%107.2014.3%$48.50m
SAGESAGE Therapeutics, Inc. 0.12%70.478.6%$43.74m
PRGOPerrigo Co. Plc -0.37%59.396.8%$43.16m
HZNPHorizon Therapeutics Plc -2.00%35.326.6%$43.12m
ZGNXZogenix, Inc. -2.81%30.059.4%$42.09m
ICPTIntercept Pharmaceuticals, Inc. 0.21%94.1116.9%$41.00m
ENDPEndo International Plc 1.15%6.188.8%$35.30m
MNKMallinckrodt Plc -0.68%5.1320.9%$34.74m

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.